玻璃体内注射拓扑替康治疗视网膜母细胞瘤玻璃体种植:91只眼的长期回顾
该回顾性非对照干预研究纳入2013年1月至2019年4月治疗的90例视网膜母细胞瘤患者的91只眼,评估玻璃体内注射拓扑替康(30 μg/0.15 ml,每4周重复至种植消退)对复发或难治性玻璃体种植的长期疗效及复发危险因素。中位随访34个月时,88只眼(97%)玻璃体种植消退,77只眼(85%)保眼成功;17只眼(19%)在平均7.9个月时出现种植复发,年龄较大和视网膜肿瘤复发显著增加复发风险。
要点
- 玻璃体内注射拓扑替康可使97%眼玻璃体种植消退,85%眼保眼成功。
- 种植形态对应所需注射次数:粉尘2.5次、球状3次、云状5次。
- 年龄较大和视网膜肿瘤复发是种植复发的危险因素。
核心结论
- 玻璃体内注射拓扑替康按每3至4周方案对难治性和复发性玻璃体种植均有效。
- 玻璃体种植的形态特征与达到消退所需的注射次数相对应。
- 年龄增长和视网膜肿瘤复发增加玻璃体内注射拓扑替康治疗后玻璃体种植复发的风险。
研究设计与样本
- 回顾性、非对照、干预性研究,纳入2013年1月至2019年4月治疗的90例视网膜母细胞瘤患者的91只眼。
- 纳入分析的患者要求至少随访12个月。
- 对完成静脉或动脉化疗后复发或难治性玻璃体种植的患者,采用安全增强技术行玻璃体内注射拓扑替康30 μg/0.15 ml,每4周重复直至种植消退。
主要发现
- 患者中位年龄18个月,D组58只眼(64%)、E组26只眼(29%)。
- 玻璃体种植为难治性46只眼(51%)、复发性45只眼(49%)。
- 共行317次玻璃体内注射,中位注射3次;中位所需注射次数:粉尘状2.5次、球状3次、云状5次。
- 玻璃体内注射后17只眼(19%)在平均随访7.9个月时出现玻璃体种植复发。
- 平均随访34个月时,88只眼(97%)玻璃体种植消退,77只眼(85%)保眼成功。
临床怎么用
- 作者报告玻璃体内注射拓扑替康按每3至4周方案对难治性和复发性玻璃体种植均有效。
- 作者报告玻璃体种植形态特征与所需注射次数相关,年龄增长和视网膜肿瘤复发增加治疗后种植复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the long-term efficacy of intravitreal topotecan (IVT) for vitreous seeds in eyes with retinoblastoma and risk factors for their recurrence. DESIGN: Retrospective, non-comparative, interventional study. PARTICIPANTS: Ninety-one eyes of 90 patients with retinoblastoma treated between January 2013 and April 2019. METHODS: Patients with recurrent or refractory vitreous seeds after completion of intravenous or intra-arterial chemotherapy were treated with IVT (30 μg/0.15 ml) by the safety-enhanced technique. The injection was repeated every 4 weeks until the regression of seeds. Patients with a minimum follow-up of 12 months were included in the analysis. MAIN OUTCOME MEASURES: Primary outcome measures were vitreous seed regression and eye salvage. Secondary outcomes were risk factors for vitreous seed recurrence after treatment with IVT, vision salvage, and complications of IVT. RESULTS: The median age of the patients was 18 months, with most having group D (n = 58 [64%]) and group E (n = 26 [29%]) retinoblastoma. Vitreous seeds were refractory in 46 eyes (51%) and recurrent in 45 eyes (49%). A total of 317 IVT injections were administered, with the median being 3 injections. The median number of IVT injections required was 2.5 injections for dust, 3 injections for sphere, and 5 injections for cloud morphologic features. Recurrence of vitreous seeds after IVT was seen in 17 eyes (19%) at a mean follow-up of 7.9 months. At a mean follow-up 34 months, vitreous seed regression was achieved in 88 eyes (97%) and eye salvage was achieved in 77 eyes (85%). Older age (P = 0.018) and recurrence of retinal tumor (15/17 eyes; P < 0.01) significantly increased the risk of vitreous seed recurrence. Cataract was the most common complication seen in 17 eyes (9%). CONCLUSIONS: Intravitreal topotecan at an every 3- to 4-week regimen is effective against both refractory and recurrent vitreous seeds. The vitreous seed morphologic features correspond to the number of injections required for regression. Increasing age and recurrence of retinal tumor increase the risk of vitreous seed recurrence after treatment with IVT. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Sen M, Rao R, Mulay K, et al. Intravitreal Topotecan for Vitreous Seeds in Retinoblastoma: A Long-term Review of 91 Eyes. Ophthalmology. 2024. PMID: 38703794. doi:10.1016/j.ophtha.2024.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。